New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe ...
Danny Gredinberg, administrator of the DEG, shares what he's learned about documenting ADAS diagnostics in the repair ...
Busy people sometimes say that they will “sleep when they are dead.” The irony is that sleep deprivation harms your health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback